Inovio Pharmaceuticals Under Legal Investigation for Alleged SEC Violations and Misleading Statements

Inovio Pharmaceuticals Faces Legal Scrutiny Over Alleged SEC Violations

Inovio Pharmaceuticals, Inc. is currently embroiled in a legal investigation due to allegations of violations of federal securities laws. Prominent law firms, including Faruqi & Faruqi LLP, are actively soliciting investors who acquired Inovio securities between October 10, 2023, and December 26, 2025. These firms are centered on potential claims linked to misleading statements made by Inovio executives regarding the effectiveness and regulatory prospects of the CELLECTRA device and the company's Biologics License Application (BLA) for INO-3107, a treatment aimed at recurrent respiratory papillomatosis. The legal claims arise from assertions that the manufacturing processes of the CELLECTRA device were below standards, which casts doubt on the company's ability to meet FDA submission deadlines effectively.

The core of the allegations involves claims that Inovio exaggerated the likelihood of obtaining regulatory approval for INO-3107, suggesting that the necessary information to validate its BLA was insufficient. The company's latest submission to the FDA on December 29, 2025, received a standard review classification, raising further concerns regarding the credibility of prior public statements about its path to expedited processing. This development may not only impact investor confidence but could also hamper Inovio's strategic operations and product development timelines, leaving stakeholders and potential pipeline advancements in a precarious position.

As the legal proceedings unfold, investors are urged to take immediate action, as lead plaintiff applications must be submitted by April 7, 2026. The lead plaintiff plays a critical role in class action lawsuits, representing the interests of all class members and guiding the proceedings. Several legal firms are preparing to assist potential lead plaintiffs in ensuring they comprehend their rights and navigate this intricate process. It remains critical for those impacted by the allegations to stay informed and proactive about their legal options as the class action develops.

Faruqi & Faruqi LLP emphasizes the urgency of the matter, aiming to advocate for investors affected by these potential securities law infractions. The firm, known for recovering extensive settlements for investors since its founding, is highlighting the implications of these allegations not just for financial recovery, but also for the future of Inovio’s initiatives in the biopharmaceutical industry. Rosen Law Firm and Levi & Korsinsky, LLP are also in the mix, underscoring the necessity for affected investors to seek guidance and consider legal representation in light of the current uncertainties surrounding Inovio’s regulatory and operational trajectory.